Most recently, highly selective PDE3, PDE4, and PDE5 inhibitors have been developed as novel treatments for pulmonary hypertension, inflammation, and ischemic diseases (Francis et al., 2011; Page and Spina, 2011). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.